EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients

Monika E Hegi iD, Felix B Oppong, James R Perry, Wolfgang Wick iD, Roger Henriksson, Norman J Laperriere, Thierry Gorlia, Annika Malmström, Michael Weller iD

Neuro-Oncology · 03.10.2024 · 26 (10) · 1867-1875

DOI: 10.1093/neuonc/noae108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 03.07.2024. Verfasst von Monika E Hegi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurosurgery & Neuroscience Research Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Glioblastoma, Promoter Regions, Genetic, DNA Repair Enzymes, DNA Modification Methylases. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EORTC Cancer Research Fund from Belgium, Canadian Cancer Society Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment of elderly/ frail patients with glioblastoma is a balance between avoiding undue toxicity, while not withholding effective treatment. It remains debated, whether these patients should receive combined chemo-radiotherapy with temozolomide (RT/TMZ→TMZ) regardless of the O6-methylguanine DNA methyltransferase gene promoter (MGMTp) methylation status. MGMT is a well-known resistance factor blunting the treatment effect of TMZ, by repairing the most genotoxic lesion. Epigenetic silencing of the MGMTp sensitizes glioblastoma to TMZ. For risk-adapted treatment, it is of utmost importance to accurately identify patients, who will not benefit from TMZ treatment.

Methods

Here, we present a reanalysis of the clinical trials CE.6 and the pooled NOA-08 and Nordic trials in elderly glioblastoma patients that compared RT to RT/TMZ→TMZ, or RT to TMZ, respectively. For 687 patients with available MGMTp methylation data, we applied a cutoff discerning truly unmethylated glioblastoma, established in a pooled analysis of 4 clinical trials for glioblastoma, with RT/TMZ→TMZ treatment, using the same quantitative methylation-specific MGMTp PCR assay.

Results

When applying this restricted cutoff to the elderly patient population, we confirmed that glioblastoma with truly unmethylated MGMTp derived no benefit from TMZ treatment. In the Nordic/NOA-08 trials, RT was better than TMZ, suggesting little or no benefit from TMZ.

Conclusions

For evidence-based treatment of glioblastoma patients validated MGMTp methylation assays should be used that accurately identify truly unmethylated patients. Respective stratified management of patients will reduce toxicity without compromising outcomes and allow testing of more promising treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPromoter Regions, GeneticDNA Repair EnzymesDNA Modification MethylasesDNA MethylationTumor Suppressor ProteinsBrain NeoplasmsTemozolomideAntineoplastic Agents, AlkylatingHumansAgedMaleFemaleAged, 80 and overChemoradiotherapy

Stichwörter der Autor:innen

MGMT promoter methylationelderly/frail GB patientsstratified treatment

Substanzen

DNA Repair EnzymesDNA Modification MethylasesMGMT protein, humanTumor Suppressor ProteinsTemozolomideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Neurosurgery & Neuroscience Research Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • DKTK and Clinical Cooperation Unit Neurooncology, DKFZ, Heidelberg, Germany.
  • Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

ORCID-Profile: Monika E Hegi, Wolfgang Wick, Michael Weller

Förderung

  • EORTC Cancer Research Fund from Belgium
  • Canadian Cancer Society Research Institute

Zitieren

APA

Hegi, M. E., Oppong, F. B., Perry, J. R., Wick, W., Henriksson, R., Laperriere, N. J., Gorlia, T., Malmström, A., & Weller, M. (2024). No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients. Neuro-Oncology, 26(10), 1867-1875. https://doi.org/10.1093/neuonc/noae108

Vancouver

Hegi ME, Oppong FB, Perry JR, Wick W, Henriksson R, Laperriere NJ, et al. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients. Neuro-Oncology. 2024;26(10):1867-1875. doi:10.1093/neuonc/noae108

BibTeX
@article{Hegi2024,
  author = {Hegi, Monika E and Oppong, Felix B and Perry, James R and Wick, Wolfgang and Henriksson, Roger and Laperriere, Norman J and Gorlia, Thierry and Malmström, Annika and Weller, Michael},
  title = {No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {10},
  pages = {1867--1875},
  doi = {10.1093/neuonc/noae108}
}
Kostenlos starten →